Proton pump inhibitor co-therapy normalizes the increased cell turnover of the gastric mucosa both in NSAID and selective COX-2 users. [electronic resource]
Producer: 20050714Description: 75-84 p. digitalISSN:- 0394-6320
- Adult
- Anti-Inflammatory Agents, Non-Steroidal -- adverse effects
- Apoptosis -- drug effects
- Cell Count
- Cell Proliferation -- drug effects
- Cyclooxygenase 2
- Cyclooxygenase 2 Inhibitors
- Cyclooxygenase Inhibitors -- adverse effects
- DNA Damage -- drug effects
- Double-Blind Method
- Enzyme Inhibitors -- therapeutic use
- Female
- Gastric Mucosa -- pathology
- Genes, erbB-1 -- genetics
- Genes, p53 -- genetics
- Humans
- Immunohistochemistry
- In Situ Nick-End Labeling
- Male
- Membrane Proteins
- Middle Aged
- Proliferating Cell Nuclear Antigen -- metabolism
- Prostaglandin-Endoperoxide Synthases -- metabolism
- Proton Pump Inhibitors
- Stomach Ulcer -- chemically induced
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.